Navigating Headwinds: Novo Nordisk Faces a Pivotal 2026

Novo Nordisk DK0062498333

The Danish pharmaceutical giant Novo Nordisk is approaching a critical juncture. With its Q4 2025 financial results scheduled for release on February 4, the company is confronting a complex landscape defined by increasing competition and significant patent expirations. Management has already signaled that the coming year will present substantial challenges.

All eyes will be on the quarterly report, due before the Copenhagen market opens on February 4. Investors are expected to scrutinize two primary areas: the early impact of patent losses on international sales and the initial market reception for the new oral formulation of Wegovy. The subsequent management conference call will likely detail the company's strategy for balancing these competitive pressures against its growth initiatives.

The Dual Threat of Patents and Rivals

CEO Mike Doustdar prepared investors for a tougher environment during the J.P. Morgan Healthcare Conference in mid-January. He noted that 2026 would be burdened by heightened competition and the loss of patent protection in key markets. "When you have a very high market share, competition will take some of it away," Doustdar stated, according to Reuters.

The core issue is the expiration of patents that previously secured monopolies in several international markets. Eli Lilly, in particular, is emerging as a formidable competitor in the GLP-1 drug segment, where Novo Nordisk has been the leader.

Compounded Drugs Erode Pricing

An internal challenge is also mounting. Doustdar revealed that approximately 1.5 million Americans are now using unapproved, compounded versions of GLP-1 agonist drugs. These copycat medications often carry a monthly price tag of just $199—a fraction of the several hundred dollars that the branded originals can cost without insurance coverage, thereby undermining Novo Nordisk's pricing power.

Strategic Countermeasures and New Launches

In response, Novo Nordisk is deploying a three-pronged strategy: expanding production capacity, introducing higher-dose formulations, and launching novel products. The success of this approach remains to be proven.

A key element of this plan is the recent U.S. launch of oral Wegovy. The daily tablet, which received FDA approval on December 22, 2025, carries an introductory price of $149 per month. The company believes oral GLP-1 medications could capture a third or more of the total market by 2030, exceeding earlier projections. This pill is aimed at attracting male and younger patient demographics, groups that have been underrepresented in treatment so far. Whether this bet pays off is a central question for the year ahead.